Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of a Recombinant DNA-based Hyaluronidase (RDNAH/ Hylenex Recombinant) to Dissolve Fixed Amounts of a Variety of Popular Hyaluronic Acid (HA) Dermal Fillers in Human Subjects.

NCT02654522 is registered in ClinicalTrials.gov with Steve Yoelin M.D. Medical Associates, Inc. as lead sponsor.

NCT NCT02654522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02654522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of a Recombinant DNA-based Hyaluronidase (RDNAH/ Hylenex Recombinant) to Dissolve Fixed Amounts of a Variety of Popular Hyaluronic Acid (HA) Dermal Fillers in Human Subjects.
Lead sponsor
Steve Yoelin M.D. Medical Associates, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2016
Completion date
February 29, 2016
Enrollment
15 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dermal filler